Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iodixanol
Drug ID BADD_D01178
Description Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
Indications and Usage Iodixanol is a contrast agent during coronary angiography.
Marketing Status approved
ATC Code V08AB09
DrugBank ID DB01249
KEGG ID D01474
MeSH ID C044834
PubChem ID 3724
TTD Drug ID D0Y4YG
NDC Product Code 71806-222; 65219-381; 0407-2223; 65219-383; 0407-2222; 57884-0029
UNII HW8W27HTXX
Synonyms iodixanol | Visipaque | Visipaque Unique Softpac | iodixanol-320 | contrast media 2-5410-3
Chemical Information
Molecular Formula C35H44I6N6O15
CAS Registry Number 92339-11-2
SMILES CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(= C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acidosis14.01.03.002--
Acute myocardial infarction24.04.04.001; 02.02.02.0010.010670%Not Available
Acute pulmonary oedema22.01.03.005; 02.05.02.0040.014227%Not Available
Agitation17.02.05.012; 19.06.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.010670%Not Available
Amaurosis06.02.10.0010.007113%Not Available
Amnesia19.20.01.001; 17.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.193484%
Anaphylactic shock24.06.02.004; 10.01.07.0020.110258%Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.0030.010670%Not Available
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema23.04.01.001; 10.01.05.009; 22.04.02.0080.113814%Not Available
Anoxia22.02.02.009--Not Available
Anxiety19.06.02.002--
Aphasia19.21.01.001; 17.02.03.0010.021340%
Aphonia22.12.03.001; 19.19.01.002; 17.02.08.0090.010670%
Apnoea22.02.01.001--
Arrhythmia02.03.02.001--Not Available
Arterial spasm24.04.02.011--Not Available
Arthralgia15.01.02.001--
Asphyxia12.01.08.011; 22.02.02.0010.007113%Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.0100.007113%Not Available
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.002--Not Available
Back pain15.03.04.005--
Blindness cortical17.17.01.017; 06.02.10.004--Not Available
Blindness transient06.02.10.006; 17.17.01.004--Not Available
Blister23.03.01.001; 12.01.06.0020.035567%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene